Tech investors who are glum about the recent performances of their holdings have nothing on AnaptysBio (NASDAQ: ANAB). The clinical-stage biotech's shares fell off a cliff on Monday, dropping nearly 34% on very discouraging news about a clinical study.
AnaptysBio announced that its leading pipeline drug, imsidolimab, had failed to meet its primary endpoint in a phase 2 trial for the treatment of moderate to severe palmoplantar pustulosis (PPP). This is a rare autoimmune disease in which individuals experience blisters on the palms of their hands or the soles of their feet. No cure currently exists; it can only be treated.
Image source: Getty Images.
Source Fool.com